Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

作者: Federico Cappuzzo , Claudia Ligorio , Pasi A. Jänne , Luca Toschi , Elisa Rossi

DOI: 10.1200/JCO.2006.09.4300

关键词:

摘要: Purpose In non–small-cell lung cancer (NSCLC), clinical and biologic predictors for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor sensitivity have been identified in retrospective studies, there is urgent need to validate these results prospective trials. The ONCOBELL trial a phase II study evaluating gefitinib NSCLC patients who never smoked or increased EGFR gene copy number activation of the antiapoptotic protein Akt. Patients Methods was evaluated using fluorescence situ hybridization (FISH), presence phospho-Akt immunohistochemistry. Additional tests included immunohistochemistry analysis EGFR, FISH HER2, mutation K-ras. Results From November 2004 February 2006, 183 were screened, 42 enrolled onto trial. We observed one complete 19 partial responses, an overall response rate (RR) 47.6% (95% ...

参考文章(51)
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
Steven A. Ahrendt, P. Anthony Decker, Enas A. Alawi, Yong-ran Zhu, Montserrat Sanchez-Cespedes, Stephen C. Yang, George B. Haasler, André Kajdacsy-Balla, Michael J. Demeure, David Sidransky, Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. ,vol. 92, pp. 1525- 1530 ,(2001) , 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
F. Cappuzzo, E. Magrini, G. L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, A. Spreafico, C. T. Paties, L. Lombardo, C. Calandri, G. Bellezza, M. Tonato, L. Crino, Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute. ,vol. 96, pp. 1133- 1141 ,(2004) , 10.1093/JNCI/DJH217
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L. Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini, Vienna Ludovini, Elisabetta Magrini, Vanesa Gregorc, Claudio Doglioni, Angelo Sidoni, Maurizio Tonato, Wilbur A. Franklin, Lucio Crino, Paul A. Bunn, Marileila Varella-Garcia, Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 643- 655 ,(2005) , 10.1093/JNCI/DJI112
David E. Hapeman, Categorical Data Analysis Technometrics. ,vol. 33, pp. 241- 241 ,(1991) , 10.1080/00401706.1991.10484817
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
Raffaella Sordella, Daphne W Bell, Daniel A Haber, Jeffrey Settleman, Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways Science. ,vol. 305, pp. 1163- 1167 ,(2004) , 10.1126/SCIENCE.1101637